middle.news
Racura Oncology Advances Lung Cancer Fight with RC220 Trial Approval
9:06am on Monday 16th of March, 2026 AEDT
•
Healthcare
Read Story
Racura Oncology Advances Lung Cancer Fight with RC220 Trial Approval
9:06am on Monday 16th of March, 2026 AEDT
Key Points
Governance approval received from Monash Health for Phase 1 HARNESS-1 trial
Trial targets EGFR-mutated non-small cell lung cancer patients on osimertinib
RC220 aims to prevent or delay resistance to current standard therapies
Multi-centre study includes ctDNA screening and adaptive dose escalation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Racura Oncology (ASX:RAC)
OPEN ARTICLE